Search Results

You are looking at 61 - 70 of 299 items for :

Clear All
Full access

Toru Okuyama, Koji Sugano, Shinsuke Iida, Takashi Ishida, Shigeru Kusumoto and Tatsuo Akechi

VES-13 was no exception. 12 , 17 The incidence of hematologic cancer, especially malignant lymphoma and multiple myeloma, has been increasing in older patients. 18 , 19 The importance of CGA in these patients with cancer has been recognized, because

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page and Chun Chao

(CRC); bendamustine with or without rituximab (B±R) for non-Hodgkin's lymphoma (NHL); and lenalidomide with or without dexamethasone for multiple myeloma (MM). When this study was initiated, TC was established by the NCCN Myeloid Growth Factors

Full access

Raymond L. Comenzo

autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract] . Blood 2005 ; 106 : 230a . Abstract 780 . 43. Palumbo A Bertola A Musto P . Oral melphalan, prednisone, and thalidomide

Full access

Stacey W. MucCullough, David Blaisdell, Jonathan K. Kish, Pat Farmer, JaLyna Laney, Tom Valuck, Natalie Dickson, Johnetta Blakely, Dianna Shipley, Jesus Berdeja, Gregg Shepard, Bertrand M. Anz III, Carolyn Kelsey, Jack Taylor, Chadi Nabhan, Jeffrey F. Patton and Annette Powers

Background: There is 1 multiple myeloma (MM) quality metric available (treatment with bisphosphonates, developed by the American Society of Hematology) to evaluate the quality of cancer care delivered to improve patient experience and outcomes. As

Full access

Claire de Oliveira, Joyce Cheng, Kelvin Chan, Craig C. Earle, Murray Krahn and Nicole Mittmann

cancers ( Table 3 ). However, multiple myeloma and pancreatic and liver cancers were overrepresented among HC patients, whereas testicular, thyroid, and cervical cancers and melanoma were overrepresented among NHC patients. Moreover, although most patients

Full access

Ko Maung, Nelson Jen An Chao, Kelly Corbet, Ashley Morris Engemann, Cristina Gasparetto, Mitchell Horwitz, Yubin Kang, Gwynn Douglas Long, Richard D Lopez, David Rizzieri, Stefanie Sarantopoulos, Keith M. Sullivan, Anthony Derek Sung and Taewoong Choi

Background: High-dose melphalan is used in autologous stem cell transplant (auto SCT) for multiple myeloma. Generic melphalan contains Propylene Glycol (PG) as co-solvent. Since FDA approved PG-free melphalan (Evomela ® ) in 2016, there were

Full access

of Primary Central Nervous System Lymphoma El Kamar Francois G. MD Abrey Lauren E. MD 7 2004 2 2 4 4 341 341 349 349 10.6004/jnccn.2004.0028 Multiple Myeloma Clinical Practice Guidelines in Oncology 7 2004 2 2 4 4 350 350 350

Full access

Annual Conference or the NCCN General Poster Session, visit NCCN.org/AC2016 . Updated NCCN Guidelines for Patients and New NCCN Quick Guide for Multiple Myeloma Now Available NCCN has published an updated NCCN Guidelines for Patients: Multiple

Full access

7 7 9 9 What is a Patient Navigator, and Should We Have Them in Major Cancer Centers? Burstein Harold J. MD, PhD 10 2009 7 7 9 9 905 905 905 905 10.6004/jnccn.2009.0060 Multiple Myeloma Anderson Kenneth C. MD Alsina Melissa

Full access

5 5 2 2 Myeloid Growth Factor Guidelines: Moving Toward a Societal Perspective Winn Rodger J. MD 02 2007 5 5 2 2 117 117 117 117 0050117 10.6004/jnccn.2007.0013 Multiple Myeloma Guidelines 02 2007 5 5 2 2 118 118 118 118 0050118 10